The role of cytokine in regulation of the natural killer cell activity

Srpski Arhiv za Celokupno Lekarstvo

Volumn 136, Issue 7-8, 2008, Pages 423-429

  Jurišić, Vladimir ^a   Stojačić Djenić, Sladjana ^b   Čolović, Nataša ^c   Konjević, Gordana ^d  

^a UNIVERSITY OF KRAGUJEVAC   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c Institute of Haematology   (Serbia)

^d INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Activation; Apoptosis; Cytokines; IFN; IL 12; IL 17; IL 2; IL 22; IL 4; Nk cell activity; TNF

Indexed keywords

CYTOKINE;

HUMAN; IMMUNOLOGY; NATURAL KILLER CELL; PHYSIOLOGY; REVIEW;

CYTOKINES; HUMANS; KILLER CELLS, NATURAL;

EID: 58149159629     PISSN: 03708179     EISSN: None     Source Type: Journal    
DOI: 10.2298/SARH0808423J     Document Type: Article

References (55)

1. Jurišić V. Characteristics of natural killer cell. Srp Arh Celok Lek 2006; 134(1-2):71-6.
2. Konjević G, Mirjačić-Martinović K, Vuletić A, et al. Low expression of CD161 and NKG2D activating receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients. Clin Exp Metastasis 2007; 24:1-11.
3. Jurišić V, Jančić-Nedeljkov R, Konjević G, Spužić I. Decrease of NK cell activity and characteristics of peripheral blood mononuclear cells (PBMC) in a haemochromatosis. Haema 2003; 6:85-8.
4. Konjević G, Jurišić V, Baničević B, Spužić I. Difference in NK cell activity between patients with non-Hodgkin's lymphoma and Hodgkin's disease. Br J Haematology 1999; 104:144-51.
5. Konjević G, Jurišić V, Spužić I. Association of NK cell dysfunction with changes in LDH characteristics of peripheral blood lymphocytes (PBL) in breast cancer patients. Breast Cancer Res Treat 2001; 66(3):255-63.
6. Čolović M, Jurišić V. New treatment with monoclonal antibodies in haematology. In: C ̌olic ́ M, editor. Tumor Immunotherapy. Belgrade: Serbian Academy of Sciences and Arts; 2006. p.41-58.
7. Jurišić V, Srdić T, Konjević G, Spužić I. Investigation of Immunomodulating and cytotoxic effects of TNF alpha on K-562 erytroleukemic cell line. In: Čolić M, editor. Tumor Immunotherapy. Belgrade: Serbian Academy of Sciences and Arts; 2006. p.229-42.
8. Dinarello CA, Mier JW. Current concepts: Lymphokine. N Engl J Med 1987; 317:940-5.
9. Konjević G, Spužić I, Jurišić V. In-vitro effects of cytokines and cytokines receptors on the activity of NK cells. JBOUON 1996; 1(1):47-52.
10. Konjević G, Jurišić V, Spužić I. In-vitro effects of cytokines and cytokines receptors on the activity of NK cells. In: Atypas G, editor. Balkan Congress of Oncology, Monduzzi Editore, Bolona, 1996. p.9-11.
11. Paul WE. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 1991; 77:1859-70.
12. Pellegrini P, Contasta I, Berghella AM, Del Beato T, Umberto-Cacsiani C, Adorno D. The Th1 and Th2 cytokine network in healthy subjects: suggestion for experimental studies to create prognostic and diagnostic indices for biotherapeutic treatment. Cancer Biotherapy & Radiopharmaceuticals 2000; 15:267-78.
13. Zhang J, Sun R, Liu J, Wang L, Tian Y. Reverse of NK cytolysis resistance of type II cytokine predominant-human tumor cells. International Immunopharmacology 2006; 6:1176-80.
14. Leibson PJ. Viewpoint: Signal transduction during natural killer cell activation. Nat Immunol 1995; 14:117-22.
15. Chan HS, Kobayashi M, Santoli D. Mechanism of IFN-γ induction by natural killer cell stimulator factor (NKSF) = IL-12. J Immunol 1992; 148:92-8.
16. Čolović M, Jurišić V, Janković G, Jovanović D, Dimitrijević J. Interferon α sensibilization-induced fatal renal insufficiency in a patient with chronic myeloid leukemia. J Clinical Pathology 2006; 59:879-81.
17. Otraldo JR, Mason AT, Gerard JP, et al. Effects of natural and recombinant IL-2 on regulation of IFN-γ production and natural killer activity: Lack of involvement of the Tac antigen these immunoregulatory effects. J Immunol 1984; 133:779-82.
18. Wang H, Smith KA. The interleukin 2 receptor: Functional consequences of its biomolecular structure. J Exp Med 1987; 166:1055-7.
19. Arima N, Kamio M, Imada K, et al. Pseudo-high affinity interleukin 2 (IL-2) receptor lacks the third component that is essential for functional IL-2 binding and signaling. J Exp Med 1992; 176:1265-72.
20. Takeshita T, Asao H, Othani K, et al. Cloning of the γ chain of the human IL-2 receptor. Science 1992; 257:379-82.
21. Siegel JP, Sharon M, Smith PL. The IL-2 receptor β chain (p70): Role in mediating signals for LAK, NK, and proliferation activities. Science 1987; 235:75-9.
22. Alexander DR, Cantrell DA. Kinases and phosphatases in T cell activation. Immun Today 1989; 10:200-20.
23. Asao H, Takeshita T, Nakamura M, Nagata K, Sugamura K. Interleukin 2 (IL-2) induced tyrosine phosphorilation of IL-2 receptor p75. J Exp Med 1990; 171:637-44.
24. Vitte-Mony I, Carmagnat DM, Bertoglio JH. Signal transduction of interleukin-2 in human natural killer cells: Involvement of the p56 lck tyrosine kinase. Mol Immunol 1994; 31(8):623-32.
25. Voss DV, Sondel PM, Robb RJ. Characterization of the interleukin 2 receptor (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-R chain with the IL-2R β chain in functional intermediate-affinity IL-2R. J Exp Med 1992; 176:531-41.
26. Konjević G, Jović V, Jurišić V, Jelić S, Radulović S, Spužić I. IL-2-mediated augmentation of NK cell activity and activation antigen expression on NK and T cell subsets in patients with metastatic melanoma treated with interferon-α and DTIC. Clinical Experimental Metastasis 2003; 20(7):647-55.
27. Nagler A, Lanier LL, Philips JH. The effects of IL-4 on human natural killer cells. A potent regulator of IL-2 activation and proliferation. J Immunol 1988; 141:2349-51.
28. Naume B, Gately MK, Desai BB, Sundan A, Espevik T. Synergistic effects of interleukin-4 and interleukin-12 on NK cell proliferation. Cytokine 1993; 5(1):38-46.
29. Blay JY, Branellec D, Robinet E, Dugas B, Gay F, Chouaib S. Involment of cyclic adenosine monophosphate in the interleukin 4 inhibitory effect on interleukin-2-induced lymphokine-activated killer generation. J Clin Invest 1990; 85:1909-13.
30. Higuchi CM, Thompson JA, Lindgren CG, et al. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro. Cancer Res 1989; 49:6487-92.
31. Hayakawa K, Salmeron MA, Kornbluth J, Bucana C, Itoh K. The role of IL-4 in proliferation and differentiation of human natural killer cells. Study of an IL-4 dependent versus an IL-2 dependent natural killer cell clone. J Immunol 1991; 146:2453-60.
32. Olsson I, Gullberg U, Lantz M, Richter J. The receptors for regulatory molecules of hematopoiesis. Eur J Hematol 1992; 48:1-9.
33. Stotter H, Custer M. C, Bolton ES, Guedez L. IL-7 induced human lymphokine activated killer cell activity and is regulated by IL-4. J Immunol 1991; 146:150-5.
34. Kobayaschi M, Fitz L, Ryan M, Hewick R. M, Clark SC. Identification and purification of natural killer cell stimulatory factor (NKSF) J Exp Med 1989; 170:827-31.
35. Robertson MJ, Ritz J. Biology and relevance of human natural killer cells. Blood 1990; 76:2421-38.
36. Serrate SA, Schulof RF, Leonaridis L, Goldstein AL, Stein MB. Modulation of human natural killer cells cytotoxicity, lymphokine production and interleukin 2 receptor expression by thymic hormones. J Immunol 1987; 139:2338-2343.
37. Deniz G, Akdis M, Aktas E, et al. Human NK1 and NK2 subsets determined by purification of IFN-gamma secreting and IFN-gamma non secreting NK cells. Eur J Immunology 2002; 32:879-84.
38. Perihar R, Dierksheide J, Hu Y, Carson W. IL-12 enhances the natural killer cell cytokine response to AB-coated tumor cells. J Clin Investigation 2002; 110:983-92.
39. Hurst S, Muchamuel T, Gorman D, et al. New IL-17 family members promote Th1 or Th2 responses the lung: In vivo function of the novel cytokine IL-25. J Immunology 2002; 169:443-53.
40. Jovčić G, Bugarski D, Petakov M, Stanković J, Stojanović N, Milenković P. Effects of IL-17 on in viro hematopoietic progenitor cell growth and cytokine release in normal and post irradiated murine bone marrow. Growth Factors 2001; 19:61-71.
41. Jovčić G, Bugarski M, Petakov M, et al. In vivo effects of interlekine-17 on haematopoietic cells and cytokine release in normal mice. Cell Proliferation 2004; 37:401-12.
42. Bugarski D, Krstić A, Vlaški M, Patakov M, Jovčić G, Stojanović N, Milenković P. Interleukine-17 induced inhibitory effect on late stage murine erythroid bone marrow progenitors. Eur Cytokine Netw 2004; 15(3):247-54.
43. Ming WJI, Bersani L, Mantovani A. Tumor necrosis factor is chemo tactic for monocytes and polymorphonuclear leukocytes. J Immunol 1987; 138:1469-72.
44. Jurišić V, Samardžić G, Čolić S, Jurišić M. TNF-α in radicular and otontogenic cysts. 6th Cytokine conference. Proceeding book. Bolona: Monduzzi Editore; 2006. p.95-100.
45. Jurišić V, Čolović M. Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta-2 microglobulin, and clinical stage in multiple myeloma, Medical Oncology 2002; 19(3): 133-9.
46. Jurišić V, Konjević G, Bumbaširević V, Duričić B, Spužić I. TNF-α effects on induction of apoptosis on malignant lymphoma peripheral blood lymphocytes. Archive of Studenica 1998; 1:49-52.
47. Jurišić V, Konjević G, Bumbaširević V, Spužić I. Morphologycal changes in cultures lymphocytes of malignant lymphoma patients. In: Bumbas ̌irevic ́ V. 40 years of electronic microscopy in Serbia. Belgrade: Elite; 1999. p.29-30.
48. Jurišić V, Spužić I, Konjević G. A comparison of NK cell activity with effects of TNF-alpha against K-562 cells, determined by LDH release assay. Cancer Letters 1999; 138:67-72.
49. Jurišić V, Kraguljac N, Konjević G, Spužić I. TNF-α induced changes in cell membrane antigen expression on K-562 cells is associated with increased LDH release. Neoplasma 2005; 1:25-32.
50. Jurišić V, Bumbaširević V, Konjević G, Duričić B, Spužić I. TNFalpha induced changes in LDH isotype profile following triggering of apoptosis in PBMC of non-Hodgkin's lymphoma. Annals of Haematology 2004; 83:84-91.
51. Jurišić V, Bogdanović G, Kojić V, Jakimov D, Srdić T. TNF-α effects on Raji cells at different cellular level estimated by various methods. Annals of Hematology 2006; 85:86-94.
52. Jurišić V, Bogdanović G, Srdić T, Kerenji A, Baltić M, Baltić VV. The activity of TNF-alpha on PC cells pre-labelled with anti-CD45 and CD95 monoclonal antibodies. Archive of Studenica 2000; 2:56-9.
53. Jurišić V, Bogdanović G, Srdić T, Jakimov D, Mrdanović J, Baltić M, Baltić VV. Modulation of TNF-α activity in tumor PC cells using anti-CD45 and anti-CD95 monoclonal antibody. Cancer Letters 2004; 214:55-61.
54. Kerstin W, Sabat R. Interleukin-22: A novel T and NK-cell derived cytokine that regulates the biology of tissues cells. Cytokine Growth Factor 2006; 17:367-80.
55. Dumoutier L, Louahed J, Reunald JC. Cloning and characterization of IL-10 related T-cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol 2000; 164:1814-9.